Recently, a randomised phase 3 trial for the first‐line treatment of HER2‐positive advanced GC showed that trastuzumab, a humanised monoclonal antibody targeting HER2, when combined with standard chemotherapy, significantly improves an overall survival of GC patients from 11.1 months to 13.8 months 3. The gene discussed is ERBB2; the disease is gastric cancer.